Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges. The current challenge that is faced by biotech and bio[...]
Kristen Hopp, PMP, Senior Clinical Trial Project Associate speaks about Cancer Genetics integrated clinical trial services. In hematological malignancies one of the challenges is the diversity of subtypes. For these trials,[...]
Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important. As a clinical trial progresses and a more diverse patient pop[...]
Scott Clark, VP of Global Scientific Operations speaks about Cancer Genetics’ PGx services and how CGI is at the forefront of personalized medicine. Individuals respond differently to medications based on their genetic prof[...]
Panna Sharma, CEO of Cancer Genetics, Inc. speaks about Cancer genetics, a global partner for biopharma companies Globally cancer is increasing significantly and with that increase comes more complexity to understand and diag[...]
More than 80% of cancers are diagnosed in community based hospitals and clinics, but many of these facilities don’t have the resources to provide the most advanced testing services. By performing the technical component at [...]
Recorded webcast of CGIX analyst day. Held in Raleigh, North Carolina September 2014, the event featured updates on the company's portfolio and services, including the CGI's programs for heme malignancies, kidney cancer, cerv[...]
Dave Gentry interviews Panna Sharma, President and CEO of CGI, an emerging leader in DNA-based cancer diagnostics that services some of the most prestigious medical institutions in the world, on "The RedChip Money Report: Sma[...]
Mr. Ramachary works with the Bioserve India team as a senior technical officer at the Center for Cellular and Molecular Biology in Hyderabad, India. His son was diagnosed with Hodgkin's Lymphoma at the age of 7. Mr. Ramachary[...]
Narasimha Marella, Ph.D., Corporate Development Manager speaks about how Cancer Genetics can help biopharma companies overcome oncology-focused clinical trial challenges.
The current challenge that is faced by biotech and biopharmas that are involved in oncology drug development is their ability to accurately stratify and randomize patients for their clinical trials based on biomarkers.
Despite the tremendous amount of investment that goes into oncology clinical trials unfortunately they tend to have one of the lowest approval rates. Our solution to these problems is a CGI Select One program.
CGI delivers accurate, reliable and comprehensive biomarker assessment for patient stratification and randomization purposes. By levagering our state-of-the-art reference laboratories CGI can deliver unique genomic information that is useful for patient selection.
CGI has developed a number of proprietary assays in hematological as well as in solid tumors. The strength in our Select One program lays in the ability to offer disease focused suite of proprietary and non-proprietary tests that deliver diagnostic, prognostic, and theranostic value.
CGI is perfectly positioned to be a one-stop solution and a unique partner for all your oncology-focused clinical trials.
Kristen Hopp, PMP, Senior Clinical Trial Project Associate speaks about Cancer Genetics integrated clinical trial services.
In hematological malignancies one of the challenges is the diversity of subtypes. For these trials, genomic insights have become critically important. Our innovative research and our clinical expertise in these cancers makes CGI an ideal partner for these clinical trials.
Pharma companies doing hem trials can have access to our proprietary and comprehensive testing as well as off the shelf assays. Based on client needs we can also design and validate new assays. In addition to testing services, CGI Select One offers global logistics management. We can ship and receive kits from investigative sites around the world.
For oncology clinical trials, Select One helps pharmaceutical companies accelerate the drug approval process and helps get drugs to market.
Nathan Campbell, Director of Clinical Services speaks about Cancer Genetics’ Biorepository capability and how having access to samples genomic data is important.
As a clinical trial progresses and a more diverse patient population is recruited, variations in a drug’s efficacy and safety can start to arise. Unexpected adverse events can potentially kill a drug at any phase of a clinical trial.
At Cancer Genetics, we understand it is critical for investigators to be able to go back and retrospectively evaluate the underlying genomic cause of these events. Because we offer biorepository storage and clinical testing services, we make it easy to go back and find those answers.
By managing both your sample and testing we can reduce complexity of Clinical Trials and help get your drug to market.
Scott Clark, VP of Global Scientific Operations speaks about Cancer Genetics’ PGx services and how CGI is at the forefront of personalized medicine.
Individuals respond differently to medications based on their genetic profile. For oncology medications, it is extremely important to understand the underlying genetics for safety and efficacy purposes.
Pharmacogenomics can help reduce adverse effects as well as predict efficacy of certain medications. Cancer Genetics offers a comprehensive testing package to help predict patient outcome and aid in drug development. For oncologist, such genomic insight can help in patient management whereas it can help Biopharma companies during drug development.
Helping patient get the right therapy is essential to Cancer Genetics’ work. Cancer Genetics’ pharmacogenomics services puts the company at the forefront of personalized medicine.
Panna Sharma, CEO of Cancer Genetics, Inc. speaks about Cancer genetics, a global partner for biopharma companies
Globally cancer is increasing significantly and with that increase comes more complexity to understand and diagnose cancers. In countries like India or China, they expect a 5 fold increase of newly diagnosed cancers, and also significant increase of cost associated with care.
As Biotech & Pharma companies expand their clinical trials globally, there is a significant need for them to have the same global standards, the same quality results and same the data across the globe, and across multiple sites.
Biotech & Pharma companies are facing the duel challenge of decreasing the cost of their clinical trials while they need to improve the speed at which they are able to get to approval. With facilities in India & China, Cancer Genetics can ensure that all labs maintain the same level of results, the same level quality, and follow the same SOPs.
In both these countries, it is not only essential that we serve the biopharma companies, but equally essential that the patients in these countries get access to the same quality genomic tests and same standards in data that our test provide.
Cancer Genetics is expanding its footprint. Cancer Genetics is empowering the personalization of cancer treatment globally.
More than 80% of cancers are diagnosed in community based hospitals and clinics, but many of these facilities don’t have the resources to provide the most advanced testing services.
By performing the technical component at CGI Laboratories, we’re enabling the healthcare provider to render the professional component.
Through our ExpandDx program, we can help increase the range of services available at these hospitals.The ExpandDx technical only offering ensures that doctors and patients have access to the most advanced testing technologies, and empowers collaboration on difficult cases. In this way, ExpandDx helps community based hospitals keep their patients, and improve the quality of care.
One of the major challenges in doing cancer diagnostics is to find mutations that might be very important, but might be present in very low levels in the tumor due to tumor heterogeneity.
Two problems facing the traditional sequencing assay are sensitivity and throughput. By sensitivity what I mean is that there will be mutations present at a very low level such that they will not be detected and by throughput what I mean is that you can only look at a very small number of genes each time such that you will not have a very comprehensive view of the genomic profile of a tumor.
The next generation sequencing service enables us to meet the challenges of these two problems by giving us the chance to look at multiple genes simultaneously at a highly sensitive level. The NGS service offered at CGI will then help the clinicians in patient management at multiple levels such as diagnosis, prognosis, and treatment selection.
Ultimately, based on the NGS result, each patient will receive the most suitable treatment tailored for himself or herself, which is the essence of personalized medicine.
Host Dave Gentry interviews Panna Sharma, President and CEO of Cancer Genetics (NasdaqCM: CGIX), an emerging leader in DNA-based cancer diagnostics that services some of the most prestigious medical institutions in the world, on “The RedChip Money Report: Small Stocks Big Money.”
“The RedChip Money Report: Small Stocks Big Money”™ delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The weekly program airs on Fox Business as well as Bloomberg UK and Bloomberg Europe. For more information, visit: http://www.redchip.com/tv
Alison’s mom died of pancreatic cancer and her dad is a four time cancer survivor. She shares about their battles with cancer, and why she thinks the work being done at CGI is so important.
My name’s Alison Burchett, and I work in marketing. My dad, who’s now 81, is a three time survivor of colon cancer, and he’s also had prostate cancer. He was diagnosed the first time at age 35 and he jokes that he gets colon cancer every twenty years. So he had it at 35, 56, and 76. He’s planning to live for his next colon cancer, which will be twenty years from then.
My mom was diagnosed with pancreatic cancer when I was in high school, and she actually passed away from it.
Some of my earliest memories are of my dad having cancer and him recovering from that. So I remember being a really little girl and not being able to sit on my dad’s lap because he had staples in his stomach – I was probably two or three at the time. And then the next experience I had of cancer was when my mom had pancreatic cancer. And she was diagnosed when I was seventeen, and she actually had a very brief but difficult battle with her cancer. She got very sick, very fast, and spent three of her last six months in the hospital.
And then my dad had colon cancer again when I was in college and I was his primary care provider. So dealing with my dad’s cancer was a little different because he always has a plan, and he feels like he’s going to beat it no matter what; he never considers the possibility of not making it. So with him it was a little different than with my mom because we knew that she wouldn’t survive.
At cancer genetics, we develop genomic tests that can help identify the DNA changes that occurred in the cell that led to cancer. And the reason that this is so cool is that it can provide accurate prognostic and diagnostic information. And so if you know the genes that changed to cause your cancer, then you can also figure out your overall outcome, sometimes what drugs you’ll respond well to. And knowing what drugs you’ll respond to helps alleviate unnecessary treatment. It also helps people plan better for how they’re going to do treatment with their doctors.
Watching my mom go through chemotherapy treatments that we knew were not going to respond well in her system was very difficult, because she got very sick and couldn’t really participate in the last six months of her life.
So I think the work we do here at Cancer Genetics is so important because we can provide that crucial information for patients and doctors so that people get the treatment that they’ll respond best to, and the most accurate diagnostic and prognostic information available.
Mr. Ramachary works with the Bioserve India team as a senior technical officer at the Center for Cellular and Molecular Biology in Hyderabad, India. His son was diagnosed with Hodgkin’s Lymphoma at the age of 7. Mr. Ramachary shares his #SurvivorStory.
Jane, Vice President of Research and Development at CGI, talks about her own battle with Lymphoma, and how surviving Lymphoma has impacted her work.
I’m Jane Houldsworth, El Nagar (and that’s important in this setting). I was diagnosed, my official date, was March 17, St. Patrick’s Day, 2010. So I was diagnosed, I was 51, I started treatment on April 22 and the reason I had to have treatment straight away was because what I had is known as follicular lymphoma [FL]. I knew that people could live for more than twenty years with it; it’s never curable. I also had what’s known as de novo transformation to diffuse large B-cell lymphoma [DLBCL], which is an aggressive component. So the strange thing here was that these were diseases that I had done work on at the bench level. So I knew a fair bit about their genetics, and some biology, so now I was going to learn about the clinical side of them all.
So the first treatment I was a little nervous about because it’s chemotherapy – we see the movies. It wasn’t anything like the movies [laughs]. I walked in and I walked out! And the very next day I took my daughter for my driver’s test.
I found that as I went along I had neuropathy in my fingers, I couldn’t do certain things, but I could still read and still type. There were some days when I used to – I slept on the living room floor for several months. There were times when I could barely walk from the living room floor to the bathroom. So my clothes used to be out in the living room in a laundry basket. But at least I was there and I could hear all of the noise going on around me.
I met some remarkable people in treatment rooms and in hospitals, because I had to be hospitalized for the last three treatments because they went over 48 hours. So I had some remarkable experiences with people. I played chemo bingo with other people who were having chemotherapy. I met Harriett, who didn’t do anything her doctor told her to do. I even acted in there one time as a translator to Arabic to a young man who had AML, and he didn’t speak English, and he needed to pee before he could leave, so I went in without any hair or anything and told him he needed to pee in the cup in Arabic so he could leave. So I met all sorts of remarkable people during this time.
I would like my doctor to have available to him as many prognostic tests to help him to decide what I was going to be treated with, how I was going to respond, and what’s my long term outlook, which is prognosis. I wanted those tests available to him. However, I realized for my disease that there weren’t that many.
The tests that we offer here, I think, definitely would fit into that battery of tests that he may need to help make decisions. And I think that’s why the Complete program is so important. Because he may not be able to put all those pieces together – all those different individual test results – and come out with an overall “what’s my prognosis” or “what should he do” unless they’re put together at one place. And this is where I see the value of our complete program – each one of these tests is actually giving different pieces of information about the disease, and it’s important that they [the doctors] have all of those available to them. So maybe that’s how it’s impacted what I do here – making sure those Complete programs are complete.
Learn more about CGI’s Complete testing for lymphoma and leukemia at http://cancergenetics.com/laboratory-services/cll-complete/